

***Amendments to the Specification***

Amendment to the specification is sought as outlined below.

At page 1, after the title, please amend the specification as follows:

**CROSS REFERENCE TO RELATED APPLICATIONS**

The present application is a continuation of U.S. Application No. 10/019,153, filed on December 21, 2001 (now abandoned), which is the U.S. National Phase of International Application No. PCT/GB00/02459, filed internationally on June 23, 2000, which was published in the English language under PCT Article 21(2) as WO 01/00855 on January 4, 2001, which entered the U.S. National Phase as U.S. Application No. 10/019,153, on December 21, 2001 (now abandoned), which claims the benefit of U.S. Provisional Application No. 60/147,819, filed August 10, 1999, and which claims priority to GB Application No. 9914733.2, filed June 23, 1999, the disclosures of all of which are incorporated herein by reference in their entireties.

Please amend the specification at page 23, lines 1-4, as follows:

FIG. 1 shows the structure of pCLYSM construct (Normal lysozyme C-terminal DNA and amino acid sequence, SEQ ID NO.: 8; C-terminal amino acid sequence alone SEQ ID NO.: 9; Linker arm, CNBr cleavage, Calcitonin and Amidation signal DNA and amino acid sequence, SEQ ID NO.: 10).

FIG. 2A-D show ~~shows~~ the DNA sequence of pCLYSM, excluding the bacterial plasmid (SEQ ID NO.4).

Please amend the specification at page 26, lines 13-14, as follows:

The structure of pCLYSM is shown in FIG. 1, and the sequence in FIG. 2A-D.

pCLYSM consists of: